lidocaine has been researched along with ranolazine in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (22.22) | 29.6817 |
| 2010's | 11 (61.11) | 24.3611 |
| 2020's | 3 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Fredj, S; Kass, RS; Liu, H; Sampson, KJ | 1 |
| Antzelevitch, C; Belardinelli, L; Burashnikov, A; Di Diego, JM; Zygmunt, AC | 2 |
| Belardinelli, L; Dhalla, AK; Robertson, C; Wang, WQ | 1 |
| Antoons, G; Beekman, JD; Belardinelli, L; Engelen, MA; Houtman, MJ; Oros, A; Stengl, M; Vos, MA | 1 |
| Bhandari, A; Dow, JS; Kloner, RA | 1 |
| Anderson, JL; Bair, TL; Bunch, TJ; Crandall, BG; Day, JD; Lappe, DL; Mader, KM; Mahapatra, S; May, HT; Molden, J; Muhlestein, JB; Murdock, D; Osborn, JS; Weiss, JP | 1 |
| Ackerman, MJ; Bernard, CE; Beyder, A; Farrugia, G; Makielski, J; Reyes, S; Strege, PR; Terzic, A | 1 |
| Ahern, CA; Goodchild, SJ; Lee, S | 1 |
| Carter, CC; Clanachan, AS; Fatehi, M; Hamming, KS; Light, PE; Soliman, D; Wang, L; Yang, W | 1 |
| Dempsey, CE; Du, C; El Harchi, A; Hancox, JC; Zhang, Y | 1 |
| George, AL; Potet, F; Vanoye, CG | 1 |
| Akin, I; Behnes, M; Borggrefe, M; Dworacek, J; El-Battrawy, I; Lang, S; Liebe, V; Meister, S; Patocskai, B; Rudic, B; Tiburcy, M; Tülümen, E; Utikal, J; Wieland, T; Yücel, G; Zhao, Z; Zhou, XB; Zimmermann, WH | 1 |
| Bergau, D; Bystricky, W; Carter, D; Gintant, G; Kamradt, K; Maier, C; Welsh, P | 1 |
| Khazraei, H; Mirkhani, H; Shabbir, W | 1 |
| Burridge, PW; Egecioglu, DE; George, AL; Potet, F | 1 |
| Angsutararux, P; Isom, LL; Mellor, RL; Nerbonne, JM; Silva, JR; Wang, W; Zhu, W | 1 |
1 review(s) available for lidocaine and ranolazine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for lidocaine and ranolazine
| Article | Year |
|---|---|
T vector velocity: A new ECG biomarker for identifying drug effects on cardiac ventricular repolarization.
Topics: Action Potentials; Adult; Databases, Factual; Double-Blind Method; Electrocardiography; Female; Heart; Humans; Lidocaine; Male; Mexiletine; Phenethylamines; Potassium Channel Blockers; Ranolazine; Sodium Channel Blockers; Sulfonamides; Verapamil; Young Adult | 2019 |
16 other study(ies) available for lidocaine and ranolazine
| Article | Year |
|---|---|
Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action.
Topics: Acetanilides; Action Potentials; Anesthetics, Local; Animals; Anti-Arrhythmia Agents; Binding Sites; Cell Line; Computer Simulation; Dose-Response Relationship, Drug; Humans; Lidocaine; Long QT Syndrome; Mice; Mice, Transgenic; Models, Cardiovascular; Models, Molecular; Mutation; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Piperazines; Ranolazine; Sodium; Sodium Channel Blockers; Sodium Channels; Time Factors; Transfection | 2006 |
Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine.
Topics: Acetanilides; Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiotonic Agents; Dogs; Drug Evaluation, Preclinical; Heart Atria; Heart Ventricles; Ion Channels; Lidocaine; Myocytes, Cardiac; Organ Specificity; Patch-Clamp Techniques; Piperazines; Purkinje Fibers; Ranolazine; Sodium Channel Blockers | 2007 |
Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits.
Topics: Acetanilides; Action Potentials; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Anti-Arrhythmia Agents; Blood Pressure; Electrocardiography; Female; Heart Rate; Lidocaine; Methoxamine; Phenylephrine; Piperazines; Potassium Channel Blockers; Prazosin; Quaternary Ammonium Compounds; Rabbits; Ranolazine; Torsades de Pointes | 2008 |
Atrial-selective sodium channel block as a strategy for suppression of atrial fibrillation.
Topics: Acetanilides; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dogs; Electrophysiology; Heart Atria; Humans; Lidocaine; Piperazines; Propafenone; Ranolazine; Sodium Channel Blockers; Ventricular Function | 2008 |
Late na(+) current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model.
Topics: Acetanilides; Animals; Anti-Arrhythmia Agents; Atrioventricular Block; Dogs; Lidocaine; Models, Animal; Phenethylamines; Piperazines; Potassium Channel Blockers; Ranolazine; Sodium Channels; Sulfonamides; Torsades de Pointes | 2010 |
First direct comparison of the late sodium current blocker ranolazine to established antiarrhythmic agents in an ischemia/reperfusion model.
Topics: Acetanilides; Animals; Anti-Arrhythmia Agents; Enzyme Inhibitors; Female; Infusions, Intravenous; Injections, Intravenous; Lidocaine; Myocardial Reperfusion Injury; Piperazines; Random Allocation; Ranolazine; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Sotalol; Statistics, Nonparametric; Tachycardia, Ventricular; Ventricular Fibrillation | 2011 |
Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks.
Topics: Acetanilides; Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathy, Dilated; Cohort Studies; Defibrillators, Implantable; Drug Therapy, Combination; Electric Countershock; Electrocardiography; Female; Humans; Hypoglycemia; Lidocaine; Male; Mexiletine; Middle Aged; Myocardial Ischemia; Piperazines; Ranolazine; Sotalol; Stroke Volume; Tachycardia, Ventricular; Treatment Outcome | 2011 |
Ranolazine decreases mechanosensitivity of the voltage-gated sodium ion channel Na(v)1.5: a novel mechanism of drug action.
Topics: Acetanilides; Animals; Biomechanical Phenomena; Cells, Cultured; Enzyme Inhibitors; HEK293 Cells; Humans; Kidney; Lidocaine; Mice; Mice, Inbred C57BL; Models, Animal; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Patch-Clamp Techniques; Piperazines; Ranolazine; Sodium Channels; Transfection | 2012 |
Local anesthetic inhibition of a bacterial sodium channel.
Topics: Acetanilides; Anesthetics, Local; Bacillus; Benzocaine; Binding Sites; Cell Line, Transformed; Cytoplasm; Eukaryota; HEK293 Cells; Humans; Hydrophobic and Hydrophilic Interactions; Ion Channel Gating; Kinetics; Lidocaine; Piperazines; Ranolazine; Sodium; Sodium Channels | 2012 |
Late sodium current inhibition alone with ranolazine is sufficient to reduce ischemia- and cardiac glycoside-induced calcium overload and contractile dysfunction mediated by reverse-mode sodium/calcium exchange.
Topics: Acetanilides; Animals; Animals, Newborn; Calcium; Calcium Signaling; Cardiac Glycosides; Electrophysiological Phenomena; Enzyme Inhibitors; In Vitro Techniques; Ischemia; Lidocaine; Male; Myocardial Contraction; Myocardial Reperfusion Injury; Patch-Clamp Techniques; Piperazines; Ranolazine; Rats; Rats, Sprague-Dawley; Sodium Channel Blockers; Sodium-Calcium Exchanger; Transfection; Ventricular Dysfunction, Left | 2012 |
Ranolazine inhibition of hERG potassium channels: drug-pore interactions and reduced potency against inactivation mutants.
Topics: Acetanilides; Action Potentials; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Gene Expression; HEK293 Cells; Humans; Ion Transport; Lidocaine; Molecular Docking Simulation; Mutation; Patch-Clamp Techniques; Piperazines; Potassium; Protein Structure, Secondary; Protein Structure, Tertiary; Ranolazine; Structure-Activity Relationship; Transgenes | 2014 |
Use-Dependent Block of Human Cardiac Sodium Channels by GS967.
Topics: Anesthetics; Humans; Ion Channel Gating; Lidocaine; Myocardium; Pyridines; Ranolazine; Sodium Channel Blockers; Sodium Channels; Triazoles | 2016 |
Hyperthermia Influences the Effects of Sodium Channel Blocking Drugs in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Topics: Ajmaline; Flecainide; Hot Temperature; Humans; Lidocaine; Myocytes, Cardiac; Patch-Clamp Techniques; Pluripotent Stem Cells; Polymerase Chain Reaction; Ranolazine; Sodium Channel Blockers; Sodium Channels | 2016 |
Electrocardiological effects of ranolazine and lidocaine on normal and diabetic rat atrium.
Topics: Acetanilides; Action Potentials; Animals; Diabetes Mellitus, Experimental; Lidocaine; Piperazines; Ranolazine; Rats; Sodium Channel Blockers | 2021 |
GS-967 and Eleclazine Block Sodium Channels in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Topics: Action Potentials; Anti-Arrhythmia Agents; Cells, Cultured; Humans; Induced Pluripotent Stem Cells; Ion Channel Gating; Lidocaine; Myocytes, Cardiac; Oxazepines; Pyridines; Ranolazine; Sodium Channel Blockers; Sodium Channels; Triazoles | 2020 |
Modulation of the effects of class Ib antiarrhythmics on cardiac NaV1.5-encoded channels by accessory NaVβ subunits.
Topics: Animals; Anti-Arrhythmia Agents; Biomarkers, Pharmacological; Electrocardiography; Heart Atria; Heart Ventricles; Humans; Lidocaine; Mice; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Patch-Clamp Techniques; Ranolazine; Voltage-Gated Sodium Channel beta-1 Subunit; Voltage-Gated Sodium Channel Blockers | 2021 |